Edition:
United States

Regenxbio Inc (RGNX.OQ)

RGNX.OQ on NASDAQ Stock Exchange Global Select Market

69.35USD
21 Sep 2018
Change (% chg)

$-2.20 (-3.07%)
Prev Close
$71.55
Open
$71.50
Day's High
$71.70
Day's Low
$69.00
Volume
694,234
Avg. Vol
219,323
52-wk High
$85.05
52-wk Low
$23.25

Latest Key Developments (Source: Significant Developments)

Regenxbio Says Public Offering Of 2.70 Mln Common Shares Priced At $65 Per Share
Friday, 10 Aug 2018 07:30am EDT 

Aug 10 (Reuters) - Regenxbio Inc ::REGENXBIO ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 2.70 MILLION COMMON SHARES PRICED AT $65.00PER SHARE.  Full Article

Regenxbio Receives $100 Mln Accelerated License Payment
Monday, 11 Jun 2018 04:05pm EDT 

June 11 (Reuters) - Regenxbio Inc ::REGENXBIO RECEIVES $100 MILLION ACCELERATED LICENSE PAYMENT DUE TO ACQUISITION OF AVEXIS BY NOVARTIS.REGENXBIO - ACCELERATED LICENSE PAYMENT CONSISTED OF $60 MILLION IN ANNUAL FEES AND A COMMERCIAL MILESTONE FEE OF $40 MILLION.REGENXBIO INC - NOVARTIS NOW HOLDS EXCLUSIVE RIGHTS TO NAV TECHNOLOGY PLATFORM FOR DEVELOPMENT OF TREATMENTS FOR SMA.REGENXBIO INC - REGENXBIO REMAINS ELIGIBLE TO RECEIVE A POTENTIAL COMMERCIAL MILESTONE FEE.  Full Article

Regenxbio Inc Q4 Loss Per Share ‍$0.51​
Tuesday, 6 Mar 2018 04:01pm EST 

March 6 (Reuters) - Regenxbio Inc ::REGENXBIO REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS.Q4 REVENUE $2.0 MILLION.QTRLY LOSS PER SHARE ‍$0.51​.REITERATES THAT IT EXPECTS FULL-YEAR 2018 CASH BURN TO BE BETWEEN $85 MILLION AND $95 MILLION​.  Full Article

Regenxbio And Avexis Announce Expansion Of Relationship For Spinal Muscular Atrophy treatments
Monday, 8 Jan 2018 08:00am EST 

Jan 8 (Reuters) - Avexis Inc ::REGENXBIO AND AVEXIS ANNOUNCE EXPANSION OF RELATIONSHIP THROUGH AMENDED LICENSE AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF TREATMENTS FOR SPINAL MUSCULAR ATROPHY.REGENXBIO INC - COULD RECEIVE UP TO $260 MILLION, INCLUDING $140 MILLION IN GUARANTEED UPFRONT AND ANNUAL PAYMENTS.REGENXBIO INC - AMENDED AGREEMENT PERMITS ASSIGNMENT BY AVEXIS UPON A CHANGE OF CONTROL WITHOUT REGENXBIO'S CONSENT.REGENXBIO INC - AVEXIS ACQUIRES EXCLUSIVE RIGHTS TO ENTIRE NAV TECHNOLOGY PLATFORM FOR DEVELOPMENT OF TREATMENTS FOR SMA.REGENXBIO - FOR PRODUCT DEVELOPED FOR TREATMENT OF SMA USING NAV AAV9 VECTOR, CO WILL RECEIVE MID-SINGLE TO LOW DOUBLE-DIGIT ROYALTIES ON NET SALES.  Full Article

Regenxbio Provides Year-End 2017 Corporate Update
Thursday, 4 Jan 2018 04:05pm EST 

Jan 4 (Reuters) - Regenxbio Inc ::REGENXBIO PROVIDES YEAR-END 2017 CORPORATE UPDATE.- ‍ANTICIPATE INITIATING DOSING IN CLINICAL TRIALS FOR MPS I AND MPS II IN FIRST HALF 2018​.- ‍ANTICIPATE COMPLETING DOSING AND PRESENTING TOPLINE DATA FROM RGX-314 AND RGX-501 TRIALS IN LATE 2018​.- ‍ENDED 2017 WITH GREATER THAN $175 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES​.SAYS EXPECTS FULL-YEAR 2018 CASH BURN TO BE BETWEEN $85 MILLION AND $95 MILLION.  Full Article

Regenxbio Announces IND Active For Phase I/II Trial Of RGX-121 To Treat Mucopolysaccharidosis Type II
Tuesday, 19 Dec 2017 07:00am EST 

Dec 19 (Reuters) - Regenxbio Inc ::REGENXBIO ANNOUNCES IND ACTIVE FOR PHASE I/II TRIAL OF RGX-121 TO TREAT MUCOPOLYSACCHARIDOSIS TYPE II.REGENXBIO INC - ‍EXPECT TO COMMENCE TRIAL ENROLLMENT IN FIRST HALF OF 2018 FOR RGX-121​.  Full Article

Regenxbio reports third quarter financial results
Wednesday, 8 Nov 2017 04:05pm EST 

Nov 8 (Reuters) - Regenxbio Inc :Regenxbio reports third quarter 2017 financial results and recent operational highlights.Q3 loss per share $0.67.Q3 revenue $1.3 million versus $100,000.Q3 revenue view $1 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.72 -- Thomson Reuters I/B/E/S.Regenxbio Inc - ‍cash, cash equivalents and marketable securities were $191.1 million as of Sept 30, 2017, compared to $159.0 million as of December 31, 2016​.  Full Article

RTW Investments reports 5 pct passive stake in Regenxbio
Thursday, 5 Oct 2017 05:34pm EDT 

Oct 5 (Reuters) - RTW Investments:RTW Investments reports a 5 percent passive stake in Regenxbio Inc as of October 2, 2017 - SEC filing.  Full Article

Dimension Therapeutics says on termination of merger with Ultragenyx co will be required to pay Ultragenyx a termination fee of $2.9 mln-SEC filing
Tuesday, 3 Oct 2017 08:59am EDT 

Oct 3 (Reuters) - Dimension Therapeutics Inc ::Dimension Therapeutics says on termination of merger with Ultragenyx co will be required to pay Ultragenyx a termination fee of $2.9 million-SEC filing.Dimension Therapeutics-co to reimburse Ultragenyx for $2.9 million fee paid by Ultragenyx on behalf of dimension for termination of Regenxbio deal.  Full Article

Ultragenyx Pharmaceutical comments on Dimension Therapeutics' announcement
Monday, 2 Oct 2017 09:22am EDT 

Oct 2 (Reuters) - Ultragenyx Pharmaceutical: :Ultragenyx Pharmaceutical comments on dimension therapeutics' announcement that co's offer is a "superior proposal" in its merger agreement with regenxbio.Ultragenyx Pharmaceutical says is "pleased" that dimension board determined that all-cash offer to buy dimension for $6.00 per share is a superior proposal.  Full Article

Regenxbio Inc News

BRIEF-Regenxbio Receives $100 Mln Accelerated License Payment

* REGENXBIO RECEIVES $100 MILLION ACCELERATED LICENSE PAYMENT DUE TO ACQUISITION OF AVEXIS BY NOVARTIS

» More RGNX.OQ News

Earnings vs. Estimates

» More Financials